New clinical treatment

Details New clinical treatment New clinical treatment

A - Human Necessities

61

K

A61K 31/198 (2006.01) A61K 38/05 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2432570

The invention relates to the use of an effective dose of N-acetyl-L-cysteine, or a dimeric form thereof, for the manufacturing of a drug for reverting mammalian neoplasia cells of epithelial origin back to a normal differentiation whereby the abnormal proliferation of the neoplasia cells is reverted to a normal pathway.

L'invention porte sur l'utilisation d'une dose efficace de N-ac~tyl-L-cyst~~ne, ou de sa forme dim~rique, pour la production de m~dicaments ramenant les cellules n~oplasiques d'origine ~pith~liale de mammif­res ~ la diff~rentiation normale, et par l~, la prolif~ration anormale des cellules n~oplasiques au m~canisme normal.

Affiliated with

Also associated with

Rating

New clinical treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with New clinical treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and New clinical treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1346288